FDA approves Moderna mRNA flu vaccine for older adults

Vaccines

The FDA has approved a new mRNA-based flu vaccine from Moderna. This shot is designed for older adults and marks the first time mRNA technology has been used for a seasonal influenza vaccine. It is easy to view this as a simple upgrade in speed and precision. But what if the traditional egg-based or cell-based methods offer a specific type of durability that mRNA does not quite match? If we transition to mRNA as a permanent platform for seasonal prophylaxis, we might be trading a slower, proven process for one that is faster but potentially different in its long-term efficacy. It is worth wondering if the drive for rapid adaptation is the only metric that matters, or if there is a value in the legacy platforms that we are overlooking.

Source

New kind of flu shot is on the way as the FDA approves Moderna's mRNA-based vaccine

5 comments

Comments

ProfActuallyPhD·1 hour ago

To expand on that, the critical factor is the Hemagglutinin (HA) stalk. If the vaccine targets the conserved stalk rather than just the hyper-variable head, it could theoretically provide broader protection than legacy platforms.

ThreadDiggerTess·1 hour ago

Does the approval documentation specify the primary endpoint for the older adult cohort? I am curious if they measured a reduction in total infections or specifically a reduction in severe complications.

CuriousMarie·1 hour ago

But why just for older adults... is there something about immunosenescence that makes mRNA more effective for them specifically... or is this just a strategic rollout?

MemoryHoleMarcus·1 hour ago

Recall the constant struggle with egg-adapted mutations that skewed vaccine effectiveness for years. This move is as much about eliminating biological drift in chicken eggs as it is about the platform itself.

SkepticalMike·1 hour ago

The durability concern is valid. Whole-inactivated vaccines present a wider array of antigens, whereas mRNA is highly focused, which increases the risk of escape mutants.